ANI intros mexiletine hydrochloride capsules
ANI Pharmaceuticals is offering mexiletine hydrochloride capsules in dosage strengths of 150 mg, 200 mg and 250 mg.
Mexiletine hydrochloride capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.
"This is our sixth generic product launch in 2020. The launch represents an important milestone for ANI in the integration of our Oakville, Canada manufacturing site, acquired in August 2018. Mexiletine is the first new ANI product launch from the Oakville site. I congratulate the team in Oakville on achieving this milestone; we look forward to additional ANI product launches from this plant in the future,” said Patrick Walsh, ANI’s Interim president and CEO.
Mexiletine hydrochloride has a market value of approximately $16 million, according to IQVIA.